keyword
MENU ▼
Read by QxMD icon Read
search

Immunotherapy for lung cancer

keyword
https://www.readbyqxmd.com/read/29045553/randomized-controlled-trial-of-s-1-versus-docetaxel-in-patients-with-non-small-cell-lung-cancer-previously-treated-with-platinum-based-chemotherapy-east-asia-s-1-trial-in-lung-cancer
#1
H Nokihara, S Lu, T S K Mok, K Nakagawa, N Yamamoto, Y K Shi, L Zhang, R A Soo, J C Yang, S Sugawara, M Nishio, T Takahashi, K Goto, J Chang, M Maemondo, Y Ichinose, Y Cheng, W T Lim, S Morita, T Tamura
Background: Chemotherapy remains a viable option for the management of advanced non-small-cell lung cancer (NSCLC) despite recent advances in molecular targeted therapy and immunotherapy. We evaluated the efficacy of oral 5-fluorouracil-based S-1 as second- or third-line therapy compared with standard docetaxel therapy in patients with advanced NSCLC. Patients and methods: Patients with advanced NSCLC previously treated with ≥1 platinum-based therapy were randomized 1:1 to docetaxel (60 mg/m2 in Japan, 75mg/m2 at all other study sites; day 1 in a 3-week cycle) or S-1 (80-120 mg/day, depending on body surface area; days 1-28 in a 6-week cycle)...
September 29, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29045514/exploratory-analysis-of-the-association-of-depth-of-response-and-survival-in-patients-with-metastatic-non-small-cell-lung-cancer-treated-with-a-targeted-therapy-or-immunotherapy
#2
C E McCoach, G M Blumenthal, L Zhang, A Myers, S Tang, R Sridhara, P Keegan, R Pazdur, R C Doebele, D Kazandjian
Background: Response Evaluation Criteria in Solid Tumors (RECIST) permits rapid evaluation of new therapeutic strategies in cancer. However, RECIST does not capture the heterogeneity of response in highly active therapies. Depth of tumor response may provide a more granular view of response. We explored the association between, depth of response (DepOR), with overall survival (OS) and progression free survival (PFS) for patients with NSCLC being treated with an ALK inhibitor (ALKi) or an anti-PD-1 antibody (Ab)...
August 2, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29043377/-lung-cancer-what-has-been-confirmed-in-therapy
#3
REVIEW
D F Heigener, M Reck
Metastatic non-small cell lung cancer has now been subdivided into several subtypes. The five basic principles of treatment include chemotherapy, anti-angiogenic therapy, targeted therapy, immunotherapy and early palliative care. The latter should be implemented for all patients with metastatic lung cancer. The use of the other modalities depends on the histological subtype, as well as on the immunohistochemical and molecular features of the tumor.
October 17, 2017: Der Internist
https://www.readbyqxmd.com/read/29036791/globo-h-expression-is-associated-with-driver-mutations-and-pd-l1-expressions-in-stage-i-non-small-cell-lung-cancer
#4
Ching-Yao Yang, Mong-Wei Lin, Yih-Leong Chang, Chen-Tu Wu
BACKGROUND: Globo H is a tumor-associated carbohydrate antigen exclusively expressed in cancer cells rather than normal tissue. Globo H has been found on many cancers of epithelial origins, and become an attractive target for cancer vaccine. OBJECTIVES: We aimed to study the expression of Globo H in non-small cell lung cancer (NSCLC) patients, and correlated its expression with common driver mutations, clinical outcomes, and status of immune checkpoint, programmed death-ligand 1 (PD-L1)...
September 29, 2017: Cancer Biomarkers: Section A of Disease Markers
https://www.readbyqxmd.com/read/29033936/coinhibitory-receptor-expression-and-immune-checkpoint-blockade-maintaining-a-balance-in-cd8-t-cell-responses-to-chronic-viral-infections-and-cancer
#5
REVIEW
Isobel S Okoye, Michael Houghton, Lorne Tyrrell, Khaled Barakat, Shokrollah Elahi
In cancer and chronic viral infections, T cells are exposed to persistent antigen stimulation. This results in expression of multiple inhibitory receptors also called "immune checkpoints" by T cells. Although these inhibitory receptors under normal conditions maintain self-tolerance and prevent immunopathology, their sustained expression deteriorates T cell function: a phenomenon called exhaustion. Recent advances in cancer immunotherapy involve blockade of cytotoxic T lymphocyte antigen-4 and programmed cell death 1 in order to reverse T cell exhaustion and reinvigorate immunity, which has translated to dramatic clinical remission in many cases of metastatic melanoma and lung cancer...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/29032709/putative-predictors-of-efficacy-for-immune-checkpoint-inhibitors-in-non-small-cell-lung-cancer-facing-the-complexity-of-the-immune-system
#6
Giulia Grizzi, Mario Caccese, Anastasios Gkountakos, Luisa Carbognin, Giampaolo Tortora, Emilio Bria, Sara Pilotto
In non-small-cell lung cancer (NSCLC) the recent introduction of immunotherapy in daily clinical practice produced a wave of enthusiasm, however, this was rapidly moderated by the evidence that only some patients could experience a relevant clinical benefit. Therefore, a great effort from the scientific community has been dedicated to the identification and validation of reliable biomarkers able to drive the activity of immunotherapeutic agents. Areas covered. This analysis aims to review the main findings about predictive biomarkers for immunotherapy in lung cancer, retracing the history of PD-L1 and focusing on a series of innovative candidates, such as mutational load, immune cells populations and microbiome...
October 14, 2017: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/29029512/pd-l1-expression-indicates-favorable-prognosis-for-advanced-lung-adenocarcinoma-patients-treated-with-pemetrexed
#7
Pei Zhang, Zhang Bao, Liming Xu, Jianya Zhou, Guohua Lu, Yinan Yao, Rong Liu, Qiqi Gao, Yihong Shen, Jianying Zhou
Conventional chemotherapy for lung cancer exerts anti-tumor effects through cytotoxicity, and through immunologic regulation by reducing specific T cell subsets and inducing the expression of programmed death ligand 1 (PD-L1) on tumor cells. Even though pemetrexed has shown huge potential in combination with other targeted or immune therapies, there is still little information about the values of specific immune checkpoint markers for advanced lung adenocarcinoma treated with pemetrexed. In the present study, a total of 56 patients with advanced lung adenocarcinoma, who received pemetrexed-based chemotherapy, were included retrospectively...
September 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29024572/radiological-manifestations-of-immune-related-adverse-effects-observed-in-patients-with-melanoma-undergoing-immunotherapy
#8
Parveen Sidhu, Alexander M Menzies, Georgina Long, Matteo Carlino, Shirleen Lorens, Rony Kapoor
Immunotherapy drugs work by stimulating the patient's own immune system to recognize and destroy cancer cells. This subclass of drugs is increasingly administered to patients with advanced melanoma. They are also commonly incorporated into other cancer therapies such as non-small cell lung cancer, renal cancer, head and neck cancers and Hodgkin lymphoma. The most commonly administered immunotherapeutic agents in the treatment of melanoma include programmed cell death protein 1 (PD-1) inhibitors, cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitors and a subclass of cytokines...
October 11, 2017: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/29024471/programmed-death-ligand-1-expression-in-non-small-cell-lung-carcinoma-comparison-among-cytology-small-biopsy-and-surgical-resection-specimens
#9
Jonas J Heymann, William A Bulman, David Swinarski, Carlos A Pagan, John P Crapanzano, Mehrvash Haghighi, Ladan Fazlollahi, Mark B Stoopler, Joshua R Sonett, Adrian G Sacher, Catherine A Shu, Naiyer A Rizvi, Anjali Saqi
BACKGROUND: One immunotherapeutic agent for patients with advanced non-small cell lung carcinoma, pembrolizumab, has a companion immunohistochemistry (IHC)-based assay that predicts response by quantifying programmed death-ligand 1 (PD-L1) expression. The current study assessed the feasibility of quantifying PD-L1 expression using cytologic non-small cell lung carcinoma specimens and compared the results with those from small biopsy and surgical resection specimens. METHODS: PD-L1 expression was quantified using the IHC-based 22C3 pharmDx assay, with "positivity" defined as staining in ≥50% viable tumor cells; ≥ 100 tumor cells were required for test adequacy...
October 12, 2017: Cancer
https://www.readbyqxmd.com/read/29023946/a-novel-recombinant-anti-egfr-peptide-vaccine-capable-of-active-immunization-and-reduction-of-tumor-volume-in-mice-model
#10
Majid Asadi-Ghalehni, Mohamad Javad Rasaee, Masoumeh RajabiBazl, Masood Khosravani, Majid Motaghinejad, Masoud Javanmardi, Saeed Khalili, Helmout Modjtahedi, Esmaeil Sadroddiny
Over-expression of the Epidermal Growth Factor Receptor (EGFR) has been reported in a number of human malignancies. High levels of expression of this receptor have been associated with poor survival in many such patients. Active immunizations that elicit antibodies of the desired type could be an appealing alternative for conventional passive immunization. In this regard, we decide to construct a novel recombinant peptide vaccine capable of prophylactic and therapeutic effects. A novel fusion recombinant peptide base vaccine consisting of L2 domain of murine ECD-EGFR and EGFR mimotope (EM-L2) was constructed and its prophylactic and therapeutic effects on the Lewis lung carcinoma mice (C57/BL6) model were evaluated...
October 10, 2017: Microbiology and Immunology
https://www.readbyqxmd.com/read/29020964/il-27-mediates-hla-class-i-up-regulation-which-can-be-inhibited-by-the-il-6-pathway-in-hla-deficient-small-cell-lung-cancer-cells
#11
Grazia Carbotti, Amin Reza Nikpoor, Paola Vacca, Rosaria Gangemi, Chiara Giordano, Francesco Campelli, Silvano Ferrini, Marina Fabbi
BACKGROUND: Recently, immunotherapy with anti-PD-1 antibodies has shown clinical benefit in recurrent Small Cell Lung Cancer (SCLC). Since anti-PD-1 re-activates anti-tumor Cytotoxic T Lymphocyte (CTL) responses, it is crucial to understand the mechanisms regulating HLA class I, and PD-L1 expression in HLA-negative SCLC. Here we addressed the role of IL-27, a cytokine related to both IL-6 and IL-12 families. METHODS: The human SCLC cell lines NCI-N592, -H69, -H146, -H446 and -H82 were treated in vitro with different cytokines (IL-27, IFN-γ, IL-6 or a soluble IL-6R/IL-6 chimera [sIL-6R/IL-6]) at different time points and analyzed for tyrosine-phosphorylated STAT proteins by Western blot, for surface molecule expression by immunofluorescence and FACS analyses or for specific mRNA expression by QRT-PCR...
October 11, 2017: Journal of Experimental & Clinical Cancer Research: CR
https://www.readbyqxmd.com/read/28992509/liposomes-coated-gold-nanocages-with-antigens-and-adjuvants-targeted-delivery-to-dendritic-cells-for-enhancing-antitumor-immune-response
#12
Ruijing Liang, Jun Xie, Jun Li, Ke Wang, Liping Liu, Yujie Gao, Mubashir Hussain, Guanxin Shen, Jintao Zhu, Juan Tao
For nanovaccine-based cancer immunotherapy, dendritic cells (DCs) are one of the most powerful antigen presenting cells (APCs) that initiate and promote the maturation of antigen-specific cytotoxic T lymphocytes (e.g., CD8(+) T cells) to induce the local and systemic antitumor immunity and further suppress the tumor metastasis and produce long-term protection against tumor. Thus, the activation and maturation of DCs is the prerequisite for efficient CD8(+) T cell-based antitumor immune responses, which is considered as a primary and promising task for nanovaccine engineering...
September 26, 2017: Biomaterials
https://www.readbyqxmd.com/read/28982616/the-yin-and-yang-of-leukotriene-b4-mediated-inflammation-in-cancer
#13
REVIEW
Venkatakrishna R Jala, Sobha R Bodduluri, Shuchismita R Satpathy, Zinal Chheda, Rajesh K Sharma, Bodduluri Haribabu
The high affinity leukotriene B4 receptor, BLT1 mediates chemotaxis of diverse leukocyte subsets to the sites of infection or inflammation. Whereas the pathological functions of LTB4/BLT1 axis in allergy, autoimmunity and cardiovascular disorders are well established; its role in cancer is only beginning to emerge. In this review, we summarize recent findings on LTB4/BLT1 axis enabling distinct outcomes toward tumor progression. In a mouse lung tumor model promoted by silicosis-induced inflammation, genetic deletion of BLT1 attenuated neutrophilic inflammation and tumor promotion...
October 2017: Seminars in Immunology
https://www.readbyqxmd.com/read/28980429/metabolic-characteristics-of-programmed-cell-death-ligand-1-expressing-lung-cancer-on-18-f-fluorodeoxyglucose-positron-emission-tomography-computed-tomography
#14
Kazuki Takada, Gouji Toyokawa, Tatsuro Okamoto, Shingo Baba, Yuka Kozuma, Taichi Matsubara, Naoki Haratake, Takaki Akamine, Shinkichi Takamori, Masakazu Katsura, Fumihiro Shoji, Hiroshi Honda, Yoshinao Oda, Yoshihiko Maehara
Programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) have been identified as novel targets of immunotherapy of lung cancer. In present study, we evaluated the metabolic characteristics of lung cancer by using (18) F-fluorodeoxyglucose positron emission tomography/computed tomography ((18) F-FDG PET/CT) with regard to PD-L1 protein expression. PD-L1 protein expression was evaluated by immunohistochemistry with the antibody clone SP142 in 579 surgically resected primary lung cancer patients...
October 4, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28975081/radiotherapy-for-oligometastatic-lung-cancer
#15
REVIEW
Derek P Bergsma, Joseph K Salama, Deepinder P Singh, Steven J Chmura, Michael T Milano
Non-small cell lung cancer (NSCLC) typically presents at an advanced stage, which is often felt to be incurable, and such patients are usually treated with a palliative approach. Accumulating retrospective and prospective clinical evidence, including a recently completed randomized trial, support the existence of an oligometastatic disease state wherein select individuals with advanced NSCLC may experience historically unprecedented prolonged survival with aggressive local treatments, consisting of radiotherapy and/or surgery, to limited sites of metastatic disease...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28968265/diagnostic-utility-of-pd-l1-expression-in-lung-adenocarcinoma-immunohistochemistry-and-rna-in-situ-hybridization
#16
Mohamad Mazen Gafeer, Kareem Hosny Mohammed, Claudia Ormenisan-Gherasim, Fahad Choudhary, Momin T Siddiqui, Cynthia Cohen
BACKGROUND: Programmed death receptor and programmed death ligand (PD-L1) are immunoregulatory proteins. Nonsmall cell lung cancer bypasses the immune system through the induction of protumorigenic immunosuppressive changes. The better understanding of immunology and antitumor immune responses has brought the promising development of novel immunotherapy agents like programmed death receptor checkpoint inhibitors. The aim of this study was to investigate the expression of PD-L1 in lung adenocarcinoma (ADC), comparing 2 different technologies: immunohistochemistry (IHC) by 2 methods versus RNA in situ hybridization (RISH)...
September 29, 2017: Applied Immunohistochemistry & Molecular Morphology: AIMM
https://www.readbyqxmd.com/read/28967537/immunotherapy-for-non-small-cell-lung-cancer-a-therapy-for-all-stages
#17
EDITORIAL
Rania G Aly, Raj G Vaghjiani, Prasad S Adusumilli
No abstract text is available yet for this article.
August 24, 2017: Seminars in Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/28966917/advances-on-immunotherapy-in-genitourinary-and-renal-cell-carcinoma
#18
Gregory P Botta, Eric Granowicz, Carrie Costantini
Genitourinary (GU) cancers are a group of epithelial malignancies associated with the organs involved in the excretion of urine. Renal cell, urothelial, and prostatic carcinoma are the overwhelming subtypes diagnosed by oncologists. Each of these was traditionally treated surgically when local and non-invasive. When these carcinomas spread, invade, or metastasize, surgical control lacks in efficacy. Chemotherapeutic regimens have been implemented for decades and have increased overall survival but many patients progress...
February 2017: Translational Cancer Research
https://www.readbyqxmd.com/read/28960588/prospects-for-new-lung-cancer-treatments-that-target-emt-signaling
#19
REVIEW
Yuji Otsuki, Hideyuki Saya, Yoshimi Arima
Lung cancer is the most common cancer worldwide. Treatment options for lung cancer include surgery, radiation therapy, chemotherapy, molecularly targeted therapy including epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) inhibitors, and immunotherapy. These treatments can be administered alone or in combination. Despite therapeutic advances, however, lung cancer remains the leading cause of cancer death. Recent studies have indicated that epithelial-mesenchymal transition (EMT) is associated with malignancy in various types of cancer, and activation of EMT signaling in cancer cells is widely considered to contribute to metastasis, recurrence, or therapeutic resistance...
September 27, 2017: Developmental Dynamics: An Official Publication of the American Association of Anatomists
https://www.readbyqxmd.com/read/28959173/pd-l1-expression-in-squamous-cell-carcinoma-and-adenocarcinoma-of-the-lung
#20
Urska Janzic, Izidor Kern, Andrej Janzic, Luka Cavka, Tanja Cufer
BACKGROUND: With introduction of immunotherapy (IT) into the treatment of advanced non-small-cell lung cancer (NSCLC), a need for predictive biomarker became apparent. Programmed death ligand 1 (PD-L1) protein expression is most widely explored predictive marker for response to IT. We assessed PD-L1 expression in tumor cells (TC) and immune cells (IC) of squamous-cell carcinoma (SCC) and adenocarcinoma (AC) patients. PATIENTS AND METHODS: We obtained 54 surgically resected tumor specimens and assessed PD-L1 expression by immunohistochemistry after staining them with antibody SP142 (Ventana, USA)...
September 2017: Radiology and Oncology
keyword
keyword
81506
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"